The closing price of Cytek BioSciences Inc (NASDAQ: CTKB) was $6.02 for the day, down -2.43% from the previous closing price of $6.17. On the day, 1394395 shares were traded.
Ratios:
Our analysis of CTKB’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.00 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1250.06. For the most recent quarter (mrq), Quick Ratio is recorded 5.89 and its Current Ratio is at 6.97. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 09 ’24 when Yan Ming sold 1,900 shares for $7.00 per share. The transaction valued at 13,304 led to the insider holds 6,008,502 shares of the business.
Yan Ming sold 20,000 shares of CTKB for $134,200 on Mar 19 ’24. The CHIEF TECHNOLOGY OFFICER now owns 6,010,402 shares after completing the transaction at $6.71 per share. On Mar 18 ’24, another insider, Yan Ming, who serves as the CHIEF TECHNOLOGY OFFICER of the company, sold 20,000 shares for $6.77 each. As a result, the insider received 135,400 and left with 6,030,402 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.08 while its Price-to-Book (P/B) ratio in mrq is 2.00.
Stock Price History:
Over the past 52 weeks, CTKB has reached a high of $12.31, while it has fallen to a 52-week low of $3.80.
Shares Statistics:
A total of 130.71M shares are outstanding, with a floating share count of 118.77M. Insiders hold about 9.22% of the company’s shares, while institutions hold 60.17% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by Cytek Biosciences, Inc. analysts.
EPS for the following year is $ETF, with Stocks analysts recommending between $Stocks and $Stocks.
